May 10, 2022 / 08:20PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
All right. Welcome to the afternoon session of the BofA Healthcare Conference. So my name is Geoff Meacham. I'm the senior biopharma analyst here at BofA. And we're thrilled to have Regeneron on stage with us today. And so we have Bob Landry, CFO; and we have Ryan Crowe, VP, Investor Relations. Ryan, do you want to read out the...
Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR
Yes. Just quickly on the forward-looking statements. So I'd like to remind you that remarks made today include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Regeneron's filings and the United States Securities and Exchange Commission.
Regeneron does not undertake any obligation to update any forward-looking statements. In addition, this
Regeneron Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript
May 11, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers